Merck Study of Keytruda With Chemotherapy in Endometrial Cancer Fails to Meet Endpoint
By Robb M. Stewart
Merck was hit with a setback in its efforts to expand its blockbuster cancer immunotherapy Keytruda after a late-stage study of its use in combination with chemotherapy to treat endometrial cancer failed to meet a key target.
The drugmaker said Thursday its Phase 3 Keynote-B21 trial evaluating Keytruda with chemotherapy as an adjuvant treatment, with or without radiotherapy, didn't meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.
The combination failed to meet the study's pre-specified statistical criteria for disease-free survival compared with placebo plus adjuvant chemotherapy, with or without radiotherapy, Merck said.
It said the study's other primary endpoint of overall survival wasn't formally tested since superiority wasn't reached for disease-free survival. The safety profile of Keytruda was consistent with that observed in previously reported studies and no new safety signals were identified, it said.
Keytruda, one of the world's top-selling drugs, has powered Merck for much of the past decade, and to extend sales the maker has sought to combine Keytruda with other drugs.
Merk said a full evaluation of the data from the latest study is ongoing and it will work with investigators to share the results with the scientific community.
Gursel Aktan, vice president of global clinical development at Merck Research Laboratories, said the company remained focused on continuing to build on the established role of Keytruda in advanced endometrial carcinoma through approved indications while also rapidly progressing clinical research evaluating Keytruda-based combinations and other investigational candidates in endometrial and other types of gynecologic malignancies
Merck said Health Canada had granted approval for Keytruda in combination with gemcitabine-based chemotherapy for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 09, 2024 08:15 ET (12:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now